DJIA 17,976.31 0.00 0.00%
NASDAQ 4,947.44 0.00 0.00%
S&P 500 2,077.52 -8.72 -0.42%
market minute promo

10.14 -0.10 (-0.98%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ACHN $10.14 -0.98%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.29
Previous Close $10.24
Daily Range $10.05 - $10.50
52-Week Range $2.45 - $16.87
Market Cap $1.2B
P/E Ratio -14.51
Dividend (Yield) $0.00 (0.0%)
Volume 2,655,950
Average Daily Volume 4,312,967
Current FY EPS -$0.97

Sector

Healthcare

Industry

Drug Makers

ACHILLION PHARMACEUTICALS, INC. (ACHN) Description

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases Website: http://www.achillion.com/

News & Commentary Rss Feed

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?

Gilead Sciences has become a battleground stock due to the uncertainty surrounding the future of the hep C market. Here is a look at why the bears might be right in their assessment of this top biotech stock.

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the Tape

Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog

Achillion And The Importance Of Hitting The Sweet Spot

Achillion Pharmaceuticals' HCV Treatments Are Worth The Investment

3 Things You Need to Know About Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals has a big opportunity in hepatitis C, but it also faces some risks.

'Mad Money' Lightning Round: Buy, Buy, Buy Whole Foods Markets

Why I'm Not Giving Up on This Tiny Biotech Stock (Yet)

Achillion Pharmaceuticals Inc. is working on a promising hepatitis C therapy that could reduce treatment times.

Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog

Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog

See More ACHN News...

ACHN's Top Competitors

ACHN $10.14 (-0.98%)
Current stock: ACHN
AMGN $163.30 (-0.61%)
Current stock: AMGN
GILD $99.40 (-1.28%)
Current stock: GILD
BIIB $426.99 (-1.07%)
Current stock: BIIB